Johnson & Johnson에 대한 매도 수량은 투자자에게 Johnson & Johnson의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Johnson & Johnson (NYSE:JNJ) 주식, 공매도 수량 보고

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Pharmacy,,Pills,And,Box,With,Healthcare,Store,,Shelf,And,Prescription

Government

News

Health Care

iShares Dow Jones US Pharmaceuticals Index Fund

일요일(11일) 도널드 트럼프 대통령은 전면적인 행정 명령을 통해 처방약 가격을 인하하겠다고 공언했다.무슨 일 있었나: 트럼프 대통령은 트루스 소셜(Truth Social)을 통해 새로운 행정명령에 서명할 계획을 발표했다. 대통령은 이번 행정명령이 &#34;최혜국대우&#34;(MFN) 가격 정책에 따라 &#34;미국은 전 세계에서 가장 낮은 가격을 지불하는 국가와 동일한 가격을 지불&#34;하는 것을 보장할 것이라고 밝혔다.

트럼프 &#34;처방약 가격 30~80% 인하할 행정명령에 서명할 것&#34;···최혜국대우 약가 정책 가동

Stack,Of,One,Dollar,American,Bills.,Cash,Wad,Roll.,Money

Personal Finance

배당금을 지급하고 지속적으로 배당금을 인상해온 오랜 역사를 가진 기업들은 여전히 소득 중심의 투자자들에게 매력적이다. 존슨앤드존슨, 쉐브론, 플라워스 푸드는 수년 동안 주주들에게 보답해 왔으며 최근 배당금 인상을 발표했다. 이들 회사는 현재 약 3%에서 5%의 배당 수익률을 제공한다.

패시브 인컴을 위한 종목: 존슨앤드존슨, 쉐브론 및 플라워스 푸드

citigroup shutter2

Earnings

Pre-Market Outlook

Markets

Trading Ideas

ERIC

화요일(15일) 미국 지수 선물이 하락세를 보이는 가운데, 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 시티, 뱅크오브아메리카, 존슨앤드존슨, 유나이티드항공 및 텔레폰악티에볼라예트

화요일 주목해야 할 주식: 시티, 뱅크오브아메리카, 존슨앤드존슨, 유나이티드항공 및 텔레폰악티에볼라예트

On Sunday, President Donald Trump vowed to <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">slash prescription drug prices</a> through a sweeping executive order.
What Happened: Trump took to Truth Social and announced plans to sign a new executive order. Under what he called a "most favored nation" pricing policy, the President said the executive order will ensure that "the United States will pay the same price as the Nation that pays the lowest price anywhere in the World."
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="612" height="966" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png" alt="" class="wp-image-911175" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22-190x300.png 190w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
Screenshot From President Donald Trump&#8217;s Truth Social Account
He added that prescription drug prices would drop "almost immediately, by 30% to 80%," and called the move "one of the most consequential Executive Orders in our Country's history."
In response, a user on X, formerly Twitter, expressed skepticism, saying, "It would be nice if Trump&#8217;s super important post about drug prices was really achievable. I think all Democrats would agree&#8230; But like most things Trump brags about, they are pie-in-the-sky promises that can&#8217;t and won&#8217;t actually materialize."
See Also: &nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, ‘If Trump Illegally Fires Fed Chair Powell, He'll Crash Our Markets, Cause More Economic Pain To American Families'</a>
That's where <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">billionaire entrepreneur</a> and Cost Plus Drugs founder Mark Cuban stepped in. Cuban acknowledged the ambition of Trump's plan but highlighted a more attainable path forward.
"I don't know if he can force the price, but he can force transparency, and that will help," Cuban wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I dont know if he can force the price , but he can force transparency , and that will help. He did it w hospitals Force transparency of contracts, pricing , rebates , claims and a lot could change Biggest thing he could do is encourage brand pharma to sell to cost plus drugs… <a href="https://t.co/vkz3Q2IFkn">https://t.co/vkz3Q2IFkn</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921710702743417149?ref_src=twsrc%5Etfw">May 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Last month, Trump issued a <a href="https://benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">multi-part executive order</a> targeting drug pricing transparency and Medicare cost reduction.
Earlier this month, he signed <a href="https://www.benzinga.com/news/25/05/45232993/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites">another executive order directing</a> the Food and Drug Administration to expedite approvals for domestic pharmaceutical manufacturing facilities.
The Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) rose 2.61% and 2.81%, respectively, over the past month.
Price Action: In after-hours trading, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was up 0.20%, while Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) increased by 0.32% and 0.13%, respectively. Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also saw a modest gain of 0.12%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Photo Courtesy: PeopleImages.com &#8211; Yuri A On Shutterstock.com
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

Protagonist Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), in collaboration with Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), released new clinical data from the Phase 3 ICONIC-TOTAL&nbsp;study investigating icotrokinra for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">scalp and genital psoriasis</a>.
Key findings from the high-impact skin sites cohort:
<ul class="wp-block-list">
<li>At week 16, 57% of patients treated with once daily icotrokinra achieved the study&#8217;s primary endpoint with an Investigator&#8217;s Global Assessment (IGA)&nbsp;b&nbsp;score of 0/1 (clear or almost clear skin) and a ≥2-grade improvement from baseline at Week 16 compared to 6% of <a href="https://www.benzinga.com/pressreleases/25/05/ac45315482/protagonist-announces-icotrokinra-phase-3-data-on-difficult-to-treat-scalp-and-genital-psoriasis-" target="_blank" rel="noreferrer noopener">patients receiving placebo</a>.</li>
<li>66% of patients with scalp psoriasis achieved a scalp-specific Investigator&#8217;s Global Assessment (ss-IGA)&nbsp;c&nbsp;score of 0/1 compared to 11% receiving placebo at 16 weeks.</li>
<li>77% of patients with genital psoriasis achieved a static Physician&#8217;s Global Assessment of Genitalia (sPGA-G)&nbsp;d&nbsp;score of 0/1 at 16 weeks, compared to 21% receiving placebo.</li>
<li>In the smaller subset of patients with hand/foot psoriasis, patients showed a numerically higher rate of skin clearance at Week 16, with 42% achieving a hand and/or foot Physician&#8217;s Global Assessment (hf-PGA)&nbsp;e&nbsp;score of 0/1 compared to 26% receiving placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44737545/johnson-johnson-protagonist-partnered-investigational-psoriasis-oral-pill-shows-75-of-adolescents-achieved-completely-clear-skin" rel="noreferrer noopener">Johnson &amp; Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study</a>
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44220449/why-is-protagonist-therapeutics-stock-trading-higher-on-monday" rel="noreferrer noopener">ulcerative colitis (UC)</a>.
The study met its primary endpoint of clinical response&nbsp;in all icotrokinra dose groups evaluated.
Additionally, the study demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44217207/protagonist-reports-positive-top-line-results-from-phase-2b-study-of-icotrokinra-showing-potentia" rel="noreferrer noopener">improvement at Week 12</a>.
The company also shared preclinical characterization of PN-881, the first-in-class oral peptide antagonist blocking the three dimeric forms of IL-17 (AA, AF and FF), at the Society for Investigative Dermatology (SID) Annual Meeting.
PN-881 represents Protagonist&#8217;s next generation of oral peptides for psoriasis. Key takeaways:
<ul class="wp-block-list">
<li>Exhibited nanomolar to picomolar in vitro potency comparable to UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) Bimzelx (bimekizumab) and superior (70-fold) to Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Consentyx secukinumab.</li>
<li>Showed metabolic stability in several matrices across several species, making it a suitable candidate for oral delivery.</li>
<li>Demonstrated PD-based target engagement in a mouse IL-17 challenge model after oral dosing.</li>
<li>Demonstrated dose-dependent efficacy with significant reduction in skin thickness in a 5-day rat IL-23 induced skin inflammation model after oral dosing.</li>
</ul>
Price Action: PTGX stock is up 1.87% at $44.74 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45296499/match-group-stock-falls-after-q1-revenue-decline-and-tinder-weakness-prompt-restructuring-plan" target="_blank" rel="noreferrer noopener">Investors Unmatch With Tinder Stock Following Q1 Performance</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

General

PTGX

UCBJF

UCBJY

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Johnson & Johnson Announced New Data From Phase 3 ICONIC-TOTAL Study Investigating Icotrokinra

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are <a href="https://www.benzinga.com/etfs">closely watching pharmaceutical ETFs</a> to measure market sentiment and ride out the emerging volatility. 
With President Donald Trump&#8217;s administration rehashing contentious ideas on drug pricing and manufacturing policy, the stakes are increasing — not only for Big Pharma, but for the overall healthcare investment environment.
Amid the trends, pharma-targeted ETFs are being watched under a more risk-averse lens. Each of the funds provides sector exposure, but structural idiosyncrasies — and varying levels of protection from regulation-induced shocks — are gaining heightened relevance.
<h1 class="wp-block-heading">Slicing Up The Pharma ETF Scene</h1>
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
The ETF offers concentrated exposure to large-cap U.S.-listed pharma companies. Its top holdings are Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) — companies with strong pipelines and international revenue streams.
Defensive Tilt: IHE&#8217;s emphasis on blue-chip names makes it a relatively defensive play during periods of political unrest.
Policy Sensitivity: But its large weighting in companies with substantial Medicaid and U.S. sales exposure renders it highly sensitive to pharmaceutical pricing reform in the domestic market.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
Unlike IHE, the SPDR S&amp;P Pharmaceuticals ETF uses an equal-weighting style, dispersing exposure across a larger segment of the industry, including mid- and small-cap companies such as Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>).
Diversified Risk: This format caps overconcentration in a single name and increases sensitivity to prospective M&amp;A action.
Higher Volatility: As more importance is assigned to lesser-known participants, XPH can see greater price volatility, particularly as regulatory threats play out.
VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)
Those in search of global exposure should look at PPH, which includes international powerhouses such as AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on par with U.S. behemoths.
Geopolitical Hedge: International diversification renders PPH less susceptible to U.S.-specific tariff risks or reforms.
Growth Exposure: Novo Nordisk&#8217;s dominance of GLP-1-based obesity treatment provides a high-growth component, although subject to some headwinds due to compounding alternatives in the U.S.
<h1 class="wp-block-heading">Volatility Ahead?</h1>
These ETF dynamics are unfolding against a backdrop of sweeping proposals and heightened industry-government tension. The Trump administration's <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">revived push to tether Medicaid drug prices to lower international benchmarks</a> has sent shockwaves through the pharmaceutical sector. Industry analysts estimate the pricing framework could erase as much as $1 trillion in revenue over a decade, according to Bloomberg.
Surprised by the White House&#8217;s latest move, drug industry executives have mounted a concerted lobbying effort, trying to keep the policy from taking hold in Congress. Although some Republican lawmakers, including Kentucky Rep. Brett Guthrie, have reaffirmed their opposition to global reference pricing, the proposal is still a live political threat, Bloomberg reported.
And adding to investor anxiety is Trump&#8217;s latest threat of<a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market"> sector-specific tariffs on drugs</a>. Although the Department of Commerce&#8217;s Section 232 investigation can take months, the threat of new import tariffs — particularly on Indian generics and contract-manufactured products — has already spilled over into related stocks. Insiders within the industry say the administration might move while there is a 90-day moratorium on reciprocal tariff imposition.
Not all of Washington&#8217;s signals are bearish, though. A recently signed executive order is intended to <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">lower FDA approval times for U.S. manufacturing plants</a> — potentially speeding up reshoring and encouraging investment in U.S.-based production. For more exposed domestic manufacturers and smaller company-focused ETFs such as XPH, this may be a long-term tailwind.
<h1 class="wp-block-heading">Proceed, But With Prescription-Strength Caution</h1>
For those looking for exposure to the pharma industry, ETFs are still an important tool — but their variations are more important than ever.
IHE provides stability but is heavily influenced by the success of U.S. policy.
XPH offers balanced exposure and is potentially more sensitive to reforms in domestic manufacturing.
PPH offers a global cushion, especially useful if U.S.-focused risks increase.
In the end, pharma ETFs&#8217; future may depend less on laboratory discoveries than on the political medicine doled out by Washington. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45259802/vistashares-launches-qusa-etf-targeting-15-annual-yield-with-quality-us-stocks-options-overlay">VistaShares Launches QUSA ETF, Targeting 15% Annual Yield With Quality U.S. Stocks, Options Overlay</a></li>
</ul>
Photo: Aria Armoko via Shutterstock

Sector ETFs

ETFs

Merrill Lynch Pharmaceutical HOLDRs Trust

VTRS

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> during a market dip.</a>
Here's the latest transactions made by the congresswoman in early May.
What Happened: Greene was ranked as the 24th best-performing member of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">outperforming the S&amp;P 500 </a>gain of 24.9%.
With new trades placed throughout the early months of 2025, Greene could see huge returns again during the year.
Here are her most recent trades made on May 5, as shown on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</li>
<li>BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)</li>
<li>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>)</li>
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</li>
<li>Frontline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): two separate purchases of $1,001 to $15,000</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</li>
<li>Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</li>
<li>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</li>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Merck Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</li>
<li>ServiceNow Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</li>
<li>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): two separate purchases of $1,001 to $15,000</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): two separate purchases of $1,001 to $15,000</li>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</li>
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
</ul>
In total, that's more than 50 different stocks bought and disclosed by Greene in the latest filing. Based on the purchase range of $1,001 to $15,000, this would make the transaction range over $50,000 and up to more than $800,000.
Read Also: <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">Bill Named After Nancy Pelosi Could Ban Congress Members From Trading Stocks: What You Need To Know About The &#8216;PELOSI&#8217; Act</a>
Why It's Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman's past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene&#8217;s past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order"> Bitcoin ETF </a>have drawn criticism along with the timing of her trades, as she is a close ally to President Donald Trump. 
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> brushed aside the criticism.</a>
&#8220;I think that criticism is laughable. President Trump has been talking about tariffs for decades,&#8221; Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip <a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared </a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
&#8220;I don&#8217;t place my buys and sells," Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. &#8220;He did a great job. Guess what he did. He bought the dip. And that&#8217;s what anybody that has financial sense does."
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn&#8217;t a secret.
Sen. Josh Hawley (R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).  
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
Hawley said the bill will help &#8220;restore Americans&#8217; trust in our nation&#8217;s legislative body.&#8221;
Hawley&#8217;s bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png" alt="" class="wp-image-906796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Politics

AAPL

ABBV

ADBE

AMAT

AMZN

DELL

GILD

GOOG

INTC

MELI

MSFT

NVDA

ODFL

PANW

PAYX

QCOM

SBUX

SCHW

TSLA

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

May 6, 2025 records indicate that Representative Gilbert Ray Cisneros filed a purchase of Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>), valued between $106,029 and $590,000. According to the May filing, the transaction occurred on May 6, 2025.
Currently, Aris Water Solutions shares are trading down 19.53% at $20.48.
<h3>What Representative Has Been Trading Recently</h3>
In the last three years, Gilbert Ray Cisneros completed 124 stock transactions totaling more than $2.24 million. Hawaiian Electric Indus and CACI International stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>): $15,001 - $50,000 Purchase</li>
<li>PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>): $15,001 - $50,000 Purchase</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): $15,001 - $50,000 Purchase</li>
</ul>
Here's a summary of Gilbert Ray Cisneros's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GoDaddy</td>
<td>GDDY</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S (Partial)</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>PTC</td>
<td>PTC</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>P</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>WR Berkley</td>
<td>WRB</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>Boeing</td>
<td>BA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-31</td>
</tr>
<tr>
<td>Centene</td>
<td>CNC</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-31</td>
</tr>
</tbody>
</table>
To stay updated on Gilbert Ray Cisneros's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/gilbert-ray-cisneros">government trades tool</a> for live updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARIS

GDDY

Recent Filing Shows That Rep. Gilbert Ray Cisneros Bought Over $106K Worth of Aris Water Solutions Stock

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Regulations

REGN

RHHBY

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

President Donald Trump signed an executive order Monday directing the Food and Drug Administration to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">announce new tariffs on imported medicines</a> within two weeks.
What Happened: The executive order aims to streamline the drug manufacturing approval process by eliminating unnecessary requirements and reducing the time needed to approve new U.S. production sites. 
According to the White House, building pharmaceutical manufacturing capacity currently takes &#8220;five to 10 years,&#8221; which it called &#8220;unacceptable from a national-security standpoint.&#8221;
&#8220;We don&#8217;t want to be buying our pharmaceuticals from other countries because if we&#8217;re in a war, we&#8217;re in a problem, we want to be able to make our own,&#8221; Trump said in a White House fact sheet.
See Also: <a href="https://www.benzinga.com/markets/25/05/45213562/peter-schiff-challenges-us-dominance-after-elon-musks-china-consumption-narrative-a-50-drop-in-the-dollar-could-supercharge-chinas-global-consumer-base">Peter Schiff Challenges US Dominance After Elon Musk&#8217;s China Consumption Narrative — A 50% Drop In The Dollar Could Supercharge China&#8217;s Global Consumer Base</a>
Why It Matters: The executive order comes as U.S. pharmaceutical manufacturing has significantly declined over decades, with most active drug ingredients now produced in China and other countries. According to EY analysis, reported by Reuters, the U.S. imported $203 billion in pharmaceutical products in 2023, with 73% coming from Europe, primarily Ireland, Germany and Switzerland.
For investors, this points to broader <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target">shifts in the pharmaceutical secto</a>r, with companies such as Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) already unveiling new domestic manufacturing plans in reaction to the looming tariff threats.
The pending tariffs could significantly impact <a href="https://www.benzinga.com/personal-finance/25/04/45029761/experts-warn-tariffs-could-negatively-impact-pretty-fragile-supply-of-generic-drugs">generic drug makers</a>, which provide 90% of U.S. prescriptions, possibly worsening existing shortages. There are already over 250 drug shortages nationwide, down from 323 in early 2024 but still concerning for healthcare stakeholders.
Mark Cuban, whose Cost Plus Drugs company sells medications at substantial discounts, warned the tariffs could force <a href="https://www.benzinga.com/news/25/04/44658207/mark-cuban-says-cost-plus-drugs-faces-price-hike-threat-tariffs-would-force-us-to-pass-costs-directly-to-consumers">price increases on many drugs</a>: &#8220;If we have a high tariff on drugs coming from India, we won&#8217;t have a choice but to pass those costs on to consumers.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45213365/maxine-waters-to-obstruct-cryptocurrency-hearing-plans-shadow-hearing-instead">Maxine Waters Plans Walkout From Crypto Hearing, Will Host &#8216;Shadow Hearing&#8217; Opposing Trump Family Ventures: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns

Announced clinical trial collaboration and supply agreement with Johnson &amp; Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations
&nbsp;
Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of registrational trials for both programs in 2026

ORIC

Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

<a href="https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE">https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE</a>
President Donald Trump will sign an executive order Monday to streamline regulations surrounding pharmaceutical manufacturing in the United States, according to two White House officials who spoke on the condition of anonymity to describe plans that have not been made public.
The order to incentivize domestic drug manufacturing comes ahead of possible <a href="https://www.washingtonpost.com/business/2025/04/10/tariffs-pharmaceuticals-us-drugs-cost/">tariffs on pharmaceuticals</a> — a policy that's on hold, for now, pending an investigation by the Commerce Department to determine whether importing pharmaceuticals is a threat to national security. That Section 232 investigation could be completed this summer, one of the officials said Monday.
But regardless of whether the Trump administration puts tariffs on prescription drugs, Monday's executive order seeks to incentivize more domestic manufacturing of medications.

BNTX

MRNA

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
As of April 30, 2025, Selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn&#8217;s disease, and ulcerative colitis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43910567/sanofi-teva-unveil-new-detailed-data-for-duvakitug-study-supporting-overall-efficacy-for-common-inflammatory-bowel-disease" rel="noreferrer noopener">Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease</a>
&#8220;Teva&#8217;s recent launch of two biosimilars – SELARSDI and EPYSQLI – coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy,&#8221; said Thomas Rainey, senior vice president, U.S. Biosimilars at Teva.
Approved <a target="_blank" href="https://www.globenewswire.com/news-release/2025/05/05/3073922/0/en/Teva-and-Alvotech-Announce-FDA-Approval-of-Interchangeability-for-SELARSDI-ustekinumab-aekn-with-Stelara-ustekinumab.html" rel="noreferrer noopener">presentations</a> of Selarsdi are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and 130 mg/26 mL in a single-dose vial for intravenous infusion.
Alvotech developed and produces Selarsdi using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara.
In August 2020, Teva and Alvotech entered into a strategic partnership to exclusively commercialize five Alvotech biosimilar product candidates. In July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products.
<ul>
<li>Alvotech manages development and manufacturing, while Teva is responsible for exclusive commercialization in the U.S., leveraging its experience and extensive sales and marketing infrastructure.</li>
<li>Two biosimilars developed under the Teva &#8211; Alvotech partnership have been granted FDA approval with interchangeability, including Selarsdi. In February 2024, the FDA approved Simlandi (adalimumab-ryvk), the first high-concentration, a citrate-free interchangeable biosimilar to AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Humira&nbsp;(adaliumumab), which was launched in the U.S. in May 2024.</li>
</ul>
Biologics License Applications (BLAs) for three additional biosimilar candidates developed by Alvotech in partnership with Teva have been accepted for review by the FDA:
<ul>
<li>AVT05, a proposed biosimilar for Johnson &amp; Johnson&#8217;s Simponi (golimumab) and Simponi Aria (golimumab).</li>
<li>AVT06, a proposed biosimilar for Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept).</li>
<li>Biosimilar User Fee Act (BsUFA) goal dates for approval for these BLAs are in Q4 2025.</li>
</ul>
Price Action: TEVA stock is up 2.10% at $16.53 and ALVO stock is up 0.67% at $8.22 at the last on check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45179379/motorolas-resilient-orders-solid-margins-drive-analyst-confidence-despite-tariff-risks" target="_blank" rel="noreferrer noopener">Motorola&#8217;s Resilient Orders, Solid Margins Drive Analyst Confidence Despite Tariff Risks</a></li>
</ul>
Photo: Shutterstock

Movers

ALVO

TEVA

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

President Donald Trump says he will personally phone chief executives who make business moves he dislikes, a tactic he deployed last week with Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos over planned tariff disclosures on the e‑commerce giant's site.
What Happened: In an <a href="https://www.nbcnews.com/politics/donald-trump/trump-call-ceos-plans-prices-tariffs-rcna204702">interview</a> on NBC's "Meet the Press," Trump recounted calling Bezos after Punchbowl News reported Amazon might label import fees tied to the administration's new 145% tariff on Chinese goods. "He's just a very nice guy," Trump said. "I asked him about [the <a href="https://www.benzinga.com/media/25/04/45086459/amazon-pressures-suppliers-for-discounts-may-show-tariff-related-costs-on-haul-site">tariff disclosure</a>]. He said, ‘Well, I don't want to do that,' and he took it off immediately." Amazon later confirmed the low‑cost Haul storefront had only "considered" the idea and dropped it.
Trump insisted he would ring any CEO whose actions he deemed "hurtful to the country." He framed tariffs not as consumer taxes but as incentives to reshore manufacturing. "The company eats the tariff," he told moderator Kristen Welker.
Asked whether fewer toys on store shelves would mark success, Trump replied, "Maybe the children will have <a href="https://www.benzinga.com/trading-ideas/25/05/45144516/trump-a-grinch-or-santa-for-christmas-children-will-have-two-dolls-instead-of-30-dolls">two dolls instead of thirty</a>. … We don't have to waste money on a trade deficit with China for junk we don't need."
See also: <a href="https://www.benzinga.com/personal-finance/25/05/45192749/ray-dalio-says-chasing-wealth-without-purpose-is-a-tragedy-dont-make-money-itself-the-goal">Ray Dalio Says Chasing Wealth Without Purpose Is A Tragedy: &#8216;Don&#8217;t Make Money Itself The Goal&#8217;</a>
Why It Matters: Economist Peter Schiff <a href="https://www.benzinga.com/news/25/05/45152587/trumps-call-to-jeff-bezos-over-amazons-tariff-display-earns-peter-schiffs-ire-type-of-stuff-you-migh">blasted Trump's call</a> to Jeff Bezos, calling it "the type of stuff you might expect to see in China." Sen. Elizabeth Warren followed up with a pointed letter to the Amazon founder, asking if Trump's angry phone call pushed Bezos to kill the tariff‑label plan in exchange for "promises or favors." <a href="https://www.benzinga.com/government/25/05/45128591/elizabeth-warren-asks-jeff-bezos-if-trump-threatened-retaliation-or-offered-favors-after-calling-him-very-nice-for-amazons-reversal-on-showing-tariff-fees">Warren warned</a> that scrubbing tariff costs "keeps consumers in the dark" and could signal a corrupt quid‑pro‑quo between Big Tech and the White House.
Days later, Trump marked his first 100 days back in office by welcoming more than <a href="https://www.benzinga.com/markets/equities/25/04/45060579/nvidia-johnson-johnson-hyundai-toyota-softbank-ceos-to-join-trump-at-white-house-as-he-touts-inv">two dozen corporate chiefs</a> to the White House. He used the "Investing in America" event to spotlight new spending commitments from powerhouses such as NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>), Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>), according to officials who briefed Reuters.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">Wall Street Veteran Investor Lowers Recession Risk As US-China Trade War Cools</a>

HYMTF

SFTBF

Donald Trump Vows To 'Call' Up CEOs Who Make Business Moves That Displease Him, Explains Why He Phoned Jeff Bezos To Scrap Amazon's Tariff Disclosure

Johnson &amp; Johnson (NYSE:&nbsp;JNJ) today announced new data from the TREMFYA&#xAE; (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.&nbsp;
Data from the QUASAR LTE study&nbsp;demonstrate patients treated with TREMFYA&#xAE; sustained clinical and endoscopic efficacy at Week 92: a, 1&nbsp;
<ul>
<li>72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92.</li>
<li>43% of patients were in endoscopic remission.c</li>
<li>Among patients achieving endoscopic improvementd at Week 44, 84% maintained endoscopic improvement through Week 92.</li>
</ul>
Patients treated with TREMFYA&#xAE; sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history.

Johnson & Johnson Says Data From QUASAR LTE Study Demonstrate Patients Treated With TREMFYA Sustained Clinical And Endoscopic Efficacy At Week 92

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92
SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ) today announced new data from the TREMFYA&#xAE; (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From TREMFYA Phase 3 QUASAR LTE Study In Adults With Moderately-To-Severely Active Ulcerative Colitis

TREMFYA&#xAE; subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis&nbsp;
Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA&#xAE; in Crohn's disease&nbsp;&nbsp;
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA&#xAE; (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intravenous (IV) induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA&#xAE; is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen. These findings are among 24 abstracts highlighting the Company's research being&nbsp;presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis

Investors are turning to dividend stocks to guard their portfolios against market volatility amid trade wars and recession risks. Data from <a href="https://www.spglobal.com/spdji/en/documents/research/research-sp500-dividend-aristocrats.pdf">S&amp;P Global </a>shows that from Dec. 29, 1989, through the end of February, the S&amp;P 500 Dividend Aristocrats outperformed the S&amp;P 500 in 66.67% of the months when the broader index posted a loss.
A few days ago, a dividend investor <a href="https://www.reddit.com/r/dividends/comments/1jxqcdg/finally_reached_1m_4km_income_update_on_the_story/">shared</a> his income report and investing journey on r/Dividends, a Reddit community with over 700,000 followers. The portfolio screenshots shared by the investor on the social platform showed his monthly dividend income was roughly $3,960. The investor, around 40, said he started investing at the age of 20.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
&nbsp;"At the time I never took it seriously and just putting in like 20-50$ a month," he said. "I ‘seriously' started at around 23-24 when I was putting in approx, 300$ on average (that was a huge for me back then), and now averaging at around 2-2.5k per month."
The investor said while it's difficult to see his portfolio suffering declines amid the current market environment, he's playing the "long game" and believes stocks will eventually go in a positive territory.&nbsp;
The investor said he's never been a "big spender" and has expenses of about €700 a month. He lives in Europe where cost of living is not "that high," he wrote.
"Other than that we have two old cars (20 and 15 years) &#8211; included in above expenses. We don't wear fancy clothes or spend money on impressing others (this can cost you a fortune)," he added.&nbsp;
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Let's take a look at some of the key dividend stocks in his portfolio.
Schwab U.S. Dividend Equity ETF&nbsp;
Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) tracks the Dow Jones U.S. Dividend 100 Index and provides exposure to some of the top dividend stocks trading in the U.S., including Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).&nbsp;
JPMorgan Equity Premium Income ETF&nbsp;
JPMorgan Equity Premium Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEPI#NYSE">JEPI</a>) makes money by investing in some of the most notable large-cap U.S. stocks and selling call options.&nbsp;
Ares Capital&nbsp;
Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>), a business development company, was one of the top stocks in the investor&#8217;s portfolio. He earned $1,920 in annual dividends from the stock.
Public Storage&nbsp;
Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) is a California-based REIT that operates self-storage facilities. The stock has a dividend yield of 4.1%. BofA Securities recently <a href="https://seekingalpha.com/news/4433284-public-storage-extra-space-storage-upgraded-on-positive-self-storage-reits-sector-view">upgraded</a> the stock to Buy from Neutral and raised its price target to $368 from $349.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
SPDR S&amp;P 500 ETF Trust&nbsp;
With a 1.2% dividend yield, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) provides investors exposure to the broader US market. The investor made $1,218 in annual dividends from his investment in the fund.&nbsp;
Altria Group
Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) has a dividend yield of about 7%. The tobacco giant accounted for about $800 in annual dividend income for the investor, according to the screenshots he shared on the social media platform.&nbsp;
PepsiCo Inc
Beverage giant Pepsi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) has <a href="https://www.google.com/search?q=pepsi+dividend+increase+consecuitve+years&amp;oq=pepsi+dividend+increase+consecuitve+years&amp;gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIJCAEQIRgKGKABMgkIAhAhGAoYoAEyCQgDECEYChigATIJCAQQIRgKGKABMgcIBRAhGI8CMgcIBhAhGI8C0gEINTgxN2owajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">increased</a> its dividends for over 50 consecutive years. The company recently reported first-quarter earnings that missed Wall Street estimates while revenue beat expectations. The stock yields 4%.&nbsp;
Johnson &amp; Johnson
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is one of the most reliable dividend stocks, having raised its payouts for 63 <a href="https://www.investor.jnj.com/news/news-details/2025/Johnson--Johnson-Announces-63rd-Consecutive-Year-of-Dividend-Increase-Raises-Quarterly-Dividend-by-4-8/default.aspx">consecutive</a> years. The stock is up 8% so far this year. The company recently <a href="https://seekingalpha.com/news/4431340-johnson-johnson-projects-400m-tariff-impact">flagged</a> a $400 million hit related to President Donald Trump's tariffs.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

ARCC

JEPI

SCHD

40-Year-Old Making $4K a Month in Dividends Reveals His Top 8 Stocks — 'We Don't Wear Fancy Clothes or Spend Money on Impressing Others'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.00</td>
<td>$30.8K</td>
<td align="right">332</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$820.00</td>
<td>$35.4K</td>
<td align="right">141</td>
<td>1.1K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$44.3K</td>
<td align="right">255</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$182.50</td>
<td>$28.8K</td>
<td align="right">780</td>
<td>752</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$100.00</td>
<td>$81.1K</td>
<td align="right">468</td>
<td>324</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$165.00</td>
<td>$79.9K</td>
<td align="right">302</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$85.00</td>
<td>$34.1K</td>
<td align="right">236</td>
<td>59</td>
</tr>
<tr>
<td>PODD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$35.7K</td>
<td align="right">5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding INO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on November 21, 2025. Parties traded 684 contract(s) at a $2.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $45.0 per contract. There were 332 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on May 2, 2025. Parties traded 43 contract(s) at a $820.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $836.0 per contract. There were 141 open contracts at this strike prior to today, and today 1130 contract(s) were bought and sold. 
• For RARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), we notice a call option sweep that happens to be bullish, expiring in 106 day(s) on August 15, 2025. This event was a transfer of 80 contract(s) at a $45.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $560.0 per contract. There were 255 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 22 contract(s) at a $182.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $1310.0 per contract. There were 780 open contracts at this strike prior to today, and today 752 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 163 contract(s) at a $100.00 strike. This particular put needed to be split into 53 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $500.0 per contract. There were 468 open contracts at this strike prior to today, and today 324 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 15, 2027. This event was a transfer of 65 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $79.9K, with a price of $1230.0 per contract. There were 302 open contracts at this strike prior to today, and today 65 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 413 day(s) on June 18, 2026. This event was a transfer of 33 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $34.1K, with a price of $1035.0 per contract. There were 236 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For PODD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), we notice a put option sweep that happens to be bullish, expiring in 260 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $3570.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

LNTH

PODD

RARE

8 Health Care Stocks Whale Activity In Today's Session

<a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-approval-for-imaavytm-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg">https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-approval-for-imaavytm-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg</a>
&nbsp;
<h2>First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older
IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies
gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE)</h2>
&nbsp;
&nbsp;
SPRING HOUSE, Pa., (April 30, 2025) &ndash; Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY&trade; (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG). The approval, which follows <a href="https://www.jnj.com/media-center/press-releases/nipocalimab-granted-u-s-fda-priority-review-for-the-treatment-of-generalized-myasthenia-gravis-gmg">FDA Priority Review designation</a>, offers a new treatment option in a proven class with the potential for lasting disease control in the broadest population of people living with gMG (adults and pediatric patients 12 years of age and older who are anti-acetylcholine receptor [AChR] or anti-muscle-specific kinase [MuSK] antibody positive).1

Johnson & Johnson Receives FDA Approval For IMAAVY, A New FcRn Blocker Offering Long-Lasting Disease Control In The Broadest Population Of People Living With Generalized Myasthenia Gravis

To commemorate his first 100 days back in office, President Donald Trump will host more than two dozen top executives and CEO&#8217;s at the White House this week to highlight a range of investments from some of the biggest companies in the world.
What Happened: Leaders from NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>), Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) are expected to be present at the "Investing in America" event on Wednesday, according to White House officials who spoke to Reuters. 
Trump intends to showcase recent investments in sectors like healthcare, defense, artificial intelligence, and consumer goods.
In January, Trump announced a private-sector pledge of up to $500 billion toward <a href="https://www.benzinga.com/news/25/01/43400191/openais-100-billion-texas-stargate-data-center-will-reportedly-employ-just-57-people-with-57600-annual-salaries">AI infrastructure</a> with support from OpenAI, SoftBank, and Oracle.
See Also: <a href="https://www.benzinga.com/25/04/45059552/goldman-sachs-reportedly-tells-countries-want-a-deal-keep-trump-happy">Want a Trade Deal? Keep Trump Happy, Goldman Sachs Reportedly Tells Countries</a>
Why It Matters: The event comes amid <a href="https://www.benzinga.com/markets/equities/25/04/44970516/boeing-adjusts-strategy-amid-trump-tariff-fallout-ceo-kelly-ortberg-says-wont-build-aircraft-for-customers-who-will-not-take-them-as-china-halts-deliveries">rising concerns </a>from industries dealing with tariff-induced disturbances. While Trump repeatedly <a href="https://www.benzinga.com/25/04/44811525/trump-hypes-500b-nvidia-investment-in-us-ai-supercomputers-golden-age-of-america-begins">called on global companies</a> to expand U.S. operations, automakers and manufacturers have expressed concerns over policy clarity and regulatory consistency. 
"I need clarity, and then I need consistency," said GM CEO Mary Barra last week, according to Reuters.
Despite the ambiguity, recent investments —like <a href="https://www.whitehouse.gov/articles/2025/03/more-investment-more-jobs-and-more-money-in-americans-pockets/">Hyundai's $21 billion U.S. commitment</a> and a new $5.8 billion steel plant in Louisiana — are being presented as proof of economic optimism. 
According to Reuters, White House spokesperson Kush Desai said, "Trillions in historic investment commitments since President Trump was elected from industry leaders including TSMC, Apple, and Roche demonstrate resounding confidence in the U.S. economy and dollar under this administration."
Still, with many companies waiting for more definitive trade policies before planning expansions, Trump's pitch this week will show how far investor confidence can hold amid the changing landscape. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/45047432/trump-says-i-run-the-country-and-the-world-yet-polls-plummet">Trump Says &#8216;I Run The Country And The World,&#8217; Yet Polls Plummet</a></li>
</ul>
Image Via Shutterstock

Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report

A personal injury lawsuit was filed seeking damages against Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Kaiser Permanente, alleging their antipsychotic medications Risperdal and Zyprexa, along with generic forms, contributed to the plaintiff <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">developing breast cancer</a>.
The plaintiff claims that the defendants failed to adequately warn about the serious health risks associated with their drugs, which were marketed and sold for a wide range of uses beyond their original psychiatric indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report" rel="noreferrer noopener">Trump Administration Considers Lowering US Drug Prices To International Levels: Report</a>
Eli Lilly has manufactured, promoted and distributed Zyprexa since the drug received FDA approval in September 1996.
Both Zyprexa and Risperdal are categorized as second-generation, or atypical, antipsychotics.
Although introduced after 1990, these drugs are not necessarily safer or more effective than first-generation antipsychotics, according to the lawsuit filed last Monday.
The <a href="https://drive.google.com/file/d/1wpMX1c2VQ3m9TgMJiNuvHzSOg_adNiLx/view" target="_blank" rel="noreferrer noopener">complaint</a> further alleges that the drugmakers sought to expand their market by promoting these medications for milder conditions and off-label uses, such as treating attention deficit disorders in children, dementia in the elderly and mood stabilization.
Concerns about the connection between the defendants' drugs and breast cancer reportedly emerged early after their release.
These medications have been found to elevate prolactin levels—a hormone that, when abnormally increased, can result in hyperprolactinemia.
<ul>
<li>This condition is linked to several health complications, including a higher risk of breast cancer. </li>
<li>Despite early clinical trial warnings and subsequent epidemiological studies over the past two decades reinforcing the association, the lawsuit asserts that the defendants neither properly warned consumers nor accurately reported these risks.</li>
</ul>
Instead, the lawsuit claims, the companies actively downplayed the potential dangers by misrepresenting study results and omitting crucial information from drug labels. 
Allegations state that rather than alerting the public, the companies prioritized profits, continuing to promote these costly drugs over older, safer and less expensive alternatives.
As a result, the defendants are accused of profiting billions while exposing consumers to what the lawsuit describes as a potent carcinogen and tumor promoter.
Price Action: LLY stock is down 1.85% at $868.22, and JNJ stock is up 0.21% at $154.90 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45042630/why-is-cancer-drug-developer-revolution-medicines-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?</a></li>
</ul>

Legal

Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications

Press Releases

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Johnson & Johnson expands efforts to champion the nursing workforce globally

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Barclays

Raymond James

Morgan Stanley

RBC Capital

B of A Securities

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

매도 수량

Johnson & Johnson (NYSE:JNJ) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌